Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Price Target of $4.00 According to Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been assigned a consensus rating of “Hold” from the seven analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $4.00.

Several equities analysts recently issued reports on the company. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 5th. Weiss Ratings raised Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Finally, Wall Street Zen upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd.

Werewolf Therapeutics Trading Down 3.0%

NASDAQ:HOWL opened at $0.98 on Friday. Werewolf Therapeutics has a 1 year low of $0.27 and a 1 year high of $1.83. The stock has a market cap of $47.63 million, a price-to-earnings ratio of -1.29 and a beta of 0.51. The stock has a 50-day moving average price of $0.92 and a two-hundred day moving average price of $0.65.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.36. The business had revenue of $21.00 million during the quarter, compared to the consensus estimate of $21.00 million. Sell-side analysts forecast that Werewolf Therapeutics will post -0.89 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vilga Financial Planning LLC bought a new stake in shares of Werewolf Therapeutics during the third quarter worth $49,000. Vontobel Holding Ltd. bought a new stake in Werewolf Therapeutics in the 3rd quarter valued at $55,000. BlackRock Inc. bought a new stake in Werewolf Therapeutics in the 2nd quarter valued at $37,000. Squarepoint Ops LLC acquired a new position in Werewolf Therapeutics in the 2nd quarter worth $37,000. Finally, Bank of America Corp DE acquired a new position in Werewolf Therapeutics in the 2nd quarter worth $112,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing investigational cancer immunotherapies. The company’s programs are designed to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues, with the goal of improving the effectiveness and tolerability of immune-based treatments.

Werewolf’s research is based on its proprietary INDUKINE platform, which uses molecular masking and tumor-activated mechanisms to conditionally regulate immune-stimulating proteins.